You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 High Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma Trial in Worldwide (LY3300054,

Active, not recruiting
  • Solid Tumor
  • +4 more
  • Nashville, Tennessee
  • +14 more
Jul 21, 2022

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer Trial in Worldwide (SL-279252)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • +12 more
  • Nashville, Tennessee
  • +4 more
Feb 3, 2022

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

Completed
  • Advanced Solid Tumor
  • Inosine 0.2g orally 3 times/day
  • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
  • Beijing, Beijing, China
    Qin li
Mar 30, 2023

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

Recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2022

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Tumor Trial in Houston

Active, not recruiting
  • Colon Adenocarcinoma
  • +10 more
  • Anti-PD-L1/TGFbetaRII Fusion Protein M7824
  • Houston, Texas
    M D Anderson Cancer Center
Jan 12, 2022

Solid Tumor Trial (BS006 Injection)

Not yet recruiting
  • Solid Tumor
  • BS006 Injection
  • (no location specified)
Jul 3, 2023

Gastrointestinal Tumors Trial in Beijing (68Ga-WL12 PET/CT)

Recruiting
  • Gastrointestinal Tumors
  • 68Ga-WL12 PET/CT
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 18, 2022

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Advanced Solid Tumor Trial (HLX43)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Oct 30, 2023

Advanced Solid Tumors Trial in Australia (HLX20)

Completed
  • Advanced Solid Tumors
  • Darlinghurst, New South Wales, Australia
  • +5 more
Jun 1, 2022

Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 26, 2023

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Efficacy, Safety Trial (PD-L1 inhibitor)

Not yet recruiting
  • Efficacy
  • Safety
  • PD-L1 inhibitor
  • (no location specified)
Apr 6, 2022

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Advanced Solid Tumors Trial in China (IMM2510)

Recruiting
  • Advanced Solid Tumors
  • Luoyang, Henan, China
  • +3 more
Jul 25, 2023

Solid Tumors, Adult Trial in Kaunas (NECVAX-NEO1)

Recruiting
  • Solid Tumors, Adult
  • NECVAX-NEO1
  • Kaunas, Lithuania
    Elona Juozaityte
May 16, 2022